Smarting from a patent defeat for cash cow Soliris in Europe, Alexion has dulled the pain with a phase 3 readout that sets up new filings for follow-up Ultomiris. The top-line data comes from a study ...

Understanding the ins and outs of a rare disease like atypical hemolytic uremic syndrome (aHUS) is a difficult task for anyone, but it can be especially confusing for young children, in whom the rare ...

Alexion, AstraZeneca Rare Disease has launched a new electronic storybook (e-book) to support children living with rare kidney disease, atypical Haemolytic Uraemic Syndrome (aHUS). The interactive ...

BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending ...

CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that the U.S. Food and Drug Administration (FDA) has granted the Company’s request for Priority Review ...

(Reuters) - The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's treatment for a second rare blood disorder, the company said. The treatment, Ultomiris, has already ...

Alexion Pharmaceuticals said this week it will ask federal regulators to greenlight its freshly approved blood-disorder drug Ultomiris for the treatment of a second ultra-rare disease. The New ...

Alexion Pharmaceuticals, Inc.ALXN announced that the phase III study of its long-acting C5 complement inhibitor Ultomiris, conducted in complement inhibitor-naive patients with atypical hemolytic ...

Only hours after announcing a positive recommendation in Europe for terminal complement inhibitor Soliris (eculizumab) in atypical hemolytic uremic syndrome (aHUS), Alexion Pharmaceuticals Inc. won ...

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License ...

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Phase 3 study of ULTOMIRIS™ (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its ...

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31 ...